+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Glycomics/Glycobiology Market by Product Type, Applications, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674276
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Glycomics/Glycobiology Market grew from USD 1.54 billion in 2024 to USD 1.76 billion in 2025. It is expected to continue growing at a CAGR of 16.46%, reaching USD 3.84 billion by 2030.

Unveiling the Evolving Glycomics Frontier

The field of glycomics has emerged as an essential frontier in modern life sciences, driven by the need to understand the complex structures and functions of glycans in health and disease. As our comprehension of protein glycosylation deepens, industries ranging from pharmaceutical development to diagnostics are placing unprecedented emphasis on glycan analysis. This convergence of scientific curiosity and market demand underscores the strategic importance of glycomics in next-generation biomedical research.

This executive summary distills the critical dynamics shaping the glycomics landscape, encompassing technological breakthroughs, regulatory influences, and shifting economic paradigms. By synthesizing current developments across analytical platforms, trade policies, and regional ecosystems, it provides decision-makers with a clear and concise roadmap. Our goal is to empower stakeholders with the insights needed to navigate complexity, capitalize on emerging opportunities, and mitigate potential challenges in the evolving glycomics market.

Pivotal Innovations Reshaping Glycan Analysis and Applications

The past few years have witnessed transformative innovations that are redefining how researchers analyze and interpret complex glycan structures. High-resolution mass spectrometry platforms now deliver unparalleled sensitivity and throughput, enabling detailed profiling of glycan heterogeneity in biomolecules. Concurrently, advances in microarray technologies and fluorescence-based assays have streamlined multiplexed glycan screening, facilitating parallel analysis of thousands of glycan interactions in a single experiment.

Equally impactful are the strides in computational glyco-informatics and machine learning, which convert vast datasets into actionable biological insights. AI-driven predictive models now accelerate the identification of glycan signatures linked to disease states, while cloud-based data integration platforms ensure seamless collaboration across research teams. These digital tools, combined with refined sample preparation workflows, are fostering a shift toward automated, end-to-end glycomics pipelines that drastically reduce turnaround times.

Looking ahead, strategic partnerships between instrument vendors, software developers, and academic consortia are accelerating translational research. Collaborative initiatives aimed at standardizing glycan nomenclature and reference libraries are paving the way for regulatory harmonization, ultimately enabling broader clinical adoption. Together, these innovations are propelling glycomics from a specialized niche to a cornerstone of precision medicine.

Navigating the Ripple Effects of US Tariff Adjustments in 2025

The introduction of revised United States tariffs in 2025 has created a multifaceted impact on the glycomics supply chain and cost structures. Key reagents and specialized enzymes imported from primary manufacturing hubs now carry higher duties, leading to elevated procurement costs for research laboratories and biopharmaceutical firms. This tariff increase compounds existing pressures from global logistics disruptions, prompting many organizations to reassess their sourcing strategies and inventory buffers.

Beyond direct cost inflation, these trade policy adjustments are reshaping supplier relationships and fostering regional diversification. Some manufacturers have accelerated the establishment of domestic production lines, while others are relocating critical operations to tariff-friendly zones to maintain competitive pricing. Simultaneously, end-users are exploring collaborative sourcing models, pooling demand across academic consortia and industry partnerships to leverage volume-based discounts and shared distribution networks.

Amid these shifts, strategic foresight and agile procurement planning are becoming paramount. Organizations that proactively model tariff scenarios and engage in dynamic supplier negotiations are better positioned to preserve research continuity and control budgetary impacts. As trade policies continue to evolve, responsive supply chain management will be a defining factor in sustaining momentum within the glycomics market.

Deconstructing Market Dynamics Through Product, Application, and End-User Lenses

When examining the glycomics market through the lens of product type, enzymes stand out as a critical segment due to their role in glycan synthesis and cleavage. Within this realm, glycosidases and neuramidases facilitate the selective breakdown of glycan chains, while glycosyltransferases and sialyltransferases drive the assembly of complex oligosaccharides. Protein sulfotransferases and sulfatases further expand analytical capabilities by modifying glycan sulfate profiles. Instruments represent another cornerstone, spanning glycan arrays that enable high-density screening, chromatography systems optimized for glycan separation, electrophoresis units designed for glycoprotein analysis, HPLC columns tailored for specialized separations, and mass spectrometry platforms that deliver structural elucidation at the molecular level. Complementing these tools are kits-ranging from glycan labeling and purification kits to glycoprotein labeling solutions-alongside a broad portfolio of reagents and chemicals essential for sample preparation and derivatization.

From an application standpoint, diagnostic workflows are increasingly integrating glycomics methodologies to enhance disease detection and monitoring. Cancer detection assays leverage glycan biomarkers to identify malignant transformations, genetic disorder screenings use glycosylation patterns to uncover congenital anomalies, and infectious disease platforms deploy glycan-based markers to track pathogen interactions. In parallel, therapeutic initiatives harness glycomics across drug delivery systems that exploit glycan targeting, drug development programs that optimize glycosylation for biologic efficacy, and drug discovery projects focused on glycan-modifying enzymes as novel targets.

End-user segmentation reveals distinct demand drivers across academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies. Academic centers prioritize experimental flexibility and methodological innovation, while CROs focus on scalable, validated platforms that meet regulatory standards. Pharmaceutical and biotech entities emphasize integrated solutions that accelerate bench-to-clinic transition, underscoring the importance of robust data analytics, traceability, and reproducibility. This multi-dimensional segmentation highlights the interconnected nature of product offerings, application needs, and user priorities in the glycomics ecosystem.

Regional Nuances Influencing Glycomics Adoption and Growth Trajectories

In the Americas, a combination of established research infrastructure, robust funding mechanisms, and a dense network of academic and industrial players has fostered rapid glycomics adoption. United States institutions spearhead translational research initiatives, supported by federal and private grants aimed at uncovering glycan biomarkers for oncology and rare disease diagnostics. Meanwhile, Latin American markets are emerging as cost-effective hubs for contract research, with growing investment in biotechnology incubators and public-private partnerships.

Europe, the Middle East, and Africa exhibit a diverse spectrum of market maturity and regulatory landscapes. Western European nations benefit from harmonized standards and collaborative frameworks that accelerate method standardization. In contrast, emerging economies within EMEA are investing strategically in biotech clusters and regional centers of excellence, often leveraging government incentives to attract foreign direct investment. Initiatives focused on rare diseases and vaccine development are catalyzing demand for specialized glycomics assays across the region.

Asia-Pacific is experiencing one of the highest growth trajectories, driven by substantial government support for life sciences research and a thriving biomanufacturing sector. Key markets such as China, Japan, and South Korea are rapidly expanding their glycomics capabilities, with leading academic institutions forging global partnerships. Southeast Asian nations are positioning themselves as manufacturing and service providers, capitalizing on competitive labor costs and evolving regulatory frameworks to deliver scalable glycomics solutions to both domestic and international clients.

Competitive Landscapes and Strategic Positioning of Leading Players

The competitive landscape in glycomics is defined by a blend of established instrumentation giants and specialized innovators. Major life sciences companies are investing heavily in expanding their portfolios with glycan-focused solutions, integrating chromatography, mass spectrometry, and microarray platforms into cohesive workflows. They are also forging strategic alliances with software providers to enhance data processing capabilities, as well as collaborating with academic consortia to validate novel analytical methodologies.

At the same time, niche companies are carving out distinctive positions by developing custom enzymes, unique labeling chemistries, and high-throughput glycan profiling kits. These specialized firms often operate with agile research and development cycles, enabling them to respond rapidly to emerging scientific needs and co-develop tailored solutions alongside key opinion leaders. Their focus on end-to-end service models and personalized research support is resonating with customers seeking differentiated value.

Across this spectrum, mergers and acquisitions remain a central theme. Larger players continue to acquire technology start-ups and reagent specialists to broaden their offerings and enter new market niches. Meanwhile, strategic partnerships between instrumentation providers and contract research organizations are becoming more prevalent, designed to create integrated service models that streamline customer workflows. This dynamic interplay between size, specialization, and collaboration shapes the competitive contours of the glycomics market.

Strategic Imperatives to Capitalize on Emerging Glycomics Opportunities

Industry leaders should prioritize the adoption of integrated analytical platforms that combine advanced mass spectrometry, chromatography, and microarray capabilities within modular workflows. By investing in AI-enabled data analytics and cloud-based collaboration tools, organizations can accelerate glycan profiling, streamline data interpretation, and enhance reproducibility across global research teams.

To mitigate tariff-driven cost pressures, companies must diversify their supplier base and explore strategic partnerships with domestic manufacturers. Establishing regional distribution hubs and engaging in consortium-based procurement can further optimize supply chain resilience and secure preferential pricing arrangements. Integrating flexible sourcing strategies into long-term planning will safeguard continuity as trade policies evolve.

Collaboration with regulatory stakeholders and industry consortia is also critical. Early engagement in standards-setting initiatives and participation in proficiency testing programs will facilitate regulatory harmonization and reduce time to market for glycomics-based diagnostics and therapeutics. Finally, targeting underserved application areas-such as rare disease biomarker discovery and personalized glyco-therapeutics-can unlock new revenue streams and reinforce scientific leadership.

Rigorous Framework Underpinning Comprehensive Glycomics Analysis

This report is founded on a rigorous methodology combining primary and secondary research. Key opinion leaders from academic institutions, contract research organizations, and pharmaceutical companies were interviewed to capture firsthand perspectives on technological adoption, supply chain challenges, and application trends. Secondary data sources included peer-reviewed journals, patent databases, regulatory filings, and trade records to ensure comprehensive coverage of the glycomics ecosystem.

Data validation and triangulation were conducted through cross-referencing multiple sources, allowing for the resolution of discrepancies and reinforcement of key insights. A structured segmentation framework underpinned the analysis, encompassing product types, application domains, and end-user categories. Tariff impact assessments were modeled using current trade regulations, historical import-export flows, and scenario planning techniques to estimate the cumulative effects of policy shifts.

Competitive benchmarking involved an evaluation of leading instrument manufacturers, reagent suppliers, and service providers across technological capabilities, geographic reach, and collaborative networks. Regional analyses were informed by governmental research initiatives, market entry strategies, and funding trends. Throughout the process, quality assurance protocols ensured consistency, accuracy, and clarity, resulting in a robust and actionable set of findings.

Synthesis of Insights Driving the Glycomics Frontier Forward

This executive summary synthesizes the multifaceted forces driving the glycomics frontier forward, from breakthrough analytical technologies and AI-enhanced data platforms to the strategic ramifications of evolving trade policies. The segmentation of product types, applications, and end-users reveals nuanced demand patterns, while regional insights underscore the importance of tailored market entry strategies across the Americas, EMEA, and Asia-Pacific.

The competitive landscape analysis highlights a dynamic ecosystem where established instrument leaders and agile niche players co-exist, shaping innovation through partnerships, mergers, and collaborative service models. Crucially, the actionable recommendations emphasize the need for integrated analytical platforms, diversified supply chains, and proactive regulatory engagement to maintain momentum and seize emerging opportunities.

Our conclusion affirms that success in the glycomics domain hinges on a balanced approach: leveraging advanced technologies, fostering collaborative networks, and aligning strategic initiatives with regional and policy frameworks. The rigorous research methodology ensures that these insights are grounded in validated data, offering a clear pathway to informed decision-making and sustained competitive advantage.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Enzymes
      • Glycosidases & Neuramidases
      • Glycosyltransferases & Sialytransferases
      • Protein Sulfotransferases & Sulfatases
    • Instruments
      • Arrays
      • Chromatography Instruments
      • Electrophoresis Instruments
      • HPLC Columns
      • Mass Spectrometry Instruments
    • Kits
      • Glycan Labeling Kits
      • Glycan Purification Kits
      • Glycoprotein Labeling Kits
    • Reagents & Chemicals
  • Applications
    • Diagnostics
      • Cancer Detection
      • Genetic Disorders
      • Infectious Diseases
    • Therapeutics
      • Drug Delivery Systems
      • Drug Development
      • Drug Discovery
  • End-User
    • Academic Research Institutes
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Agilent Technologies, Inc.
  • AMSBIO
  • Asparia Glycomics
  • Bio-Techne Corporation
  • Bruker Corporation
  • Chemily Glycoscience
  • Creative Diagnostics
  • FUJIFILM Wako Pure Chemical Corporation
  • Genos Glyco
  • Glycan Therapeutics
  • GlycoDiag
  • glyXera GmbH
  • ICE S.p.a.
  • Lectenz Bio, Inc.
  • Ludger Ltd
  • Megazyme Ltd. by Neogen Corporation
  • Merck KGaA
  • New England Biolabs, Inc.
  • QIAGEN N.V.
  • RayBiotech, Inc.
  • Revvity, Inc.
  • SCIEX by Danaher Corporation
  • Shimadzu Corporation
  • Sumitomo Bakelite Co., Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Vector Laboratories, Inc.
  • Waters Corporation
  • Z Biotech, LLC
  • Zacharon Pharmaceuticals, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Glycomics/Glycobiology Market, by Product Type
8.1. Introduction
8.2. Enzymes
8.2.1. Glycosidases & Neuramidases
8.2.2. Glycosyltransferases & Sialytransferases
8.2.3. Protein Sulfotransferases & Sulfatases
8.3. Instruments
8.3.1. Arrays
8.3.2. Chromatography Instruments
8.3.3. Electrophoresis Instruments
8.3.4. HPLC Columns
8.3.5. Mass Spectrometry Instruments
8.4. Kits
8.4.1. Glycan Labeling Kits
8.4.2. Glycan Purification Kits
8.4.3. Glycoprotein Labeling Kits
8.5. Reagents & Chemicals
9. Glycomics/Glycobiology Market, by Applications
9.1. Introduction
9.2. Diagnostics
9.2.1. Cancer Detection
9.2.2. Genetic Disorders
9.2.3. Infectious Diseases
9.3. Therapeutics
9.3.1. Drug Delivery Systems
9.3.2. Drug Development
9.3.3. Drug Discovery
10. Glycomics/Glycobiology Market, by End-User
10.1. Introduction
10.2. Academic Research Institutes
10.3. Contract Research Organizations
10.4. Pharmaceutical & Biotechnology Companies
11. Americas Glycomics/Glycobiology Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Glycomics/Glycobiology Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Glycomics/Glycobiology Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Agilent Technologies, Inc.
14.3.2. AMSBIO
14.3.3. Asparia Glycomics
14.3.4. Bio-Techne Corporation
14.3.5. Bruker Corporation
14.3.6. Chemily Glycoscience
14.3.7. Creative Diagnostics
14.3.8. FUJIFILM Wako Pure Chemical Corporation
14.3.9. Genos Glyco
14.3.10. Glycan Therapeutics
14.3.11. GlycoDiag
14.3.12. glyXera GmbH
14.3.13. ICE S.p.a.
14.3.14. Lectenz Bio, Inc.
14.3.15. Ludger Ltd
14.3.16. Megazyme Ltd. by Neogen Corporation
14.3.17. Merck KGaA
14.3.18. New England Biolabs, Inc.
14.3.19. QIAGEN N.V.
14.3.20. RayBiotech, Inc.
14.3.21. Revvity, Inc.
14.3.22. SCIEX by Danaher Corporation
14.3.23. Shimadzu Corporation
14.3.24. Sumitomo Bakelite Co., Ltd.
14.3.25. Takara Bio Inc.
14.3.26. Thermo Fisher Scientific Inc.
14.3.27. Tokyo Chemical Industry Co., Ltd.
14.3.28. Vector Laboratories, Inc.
14.3.29. Waters Corporation
14.3.30. Z Biotech, LLC
14.3.31. Zacharon Pharmaceuticals, Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. GLYCOMICS/GLYCOBIOLOGY MARKET MULTI-CURRENCY
FIGURE 2. GLYCOMICS/GLYCOBIOLOGY MARKET MULTI-LANGUAGE
FIGURE 3. GLYCOMICS/GLYCOBIOLOGY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLYCOMICS/GLYCOBIOLOGY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. GLYCOMICS/GLYCOBIOLOGY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GLYCOMICS/GLYCOBIOLOGY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCOSIDASES & NEURAMIDASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCOSYLTRANSFERASES & SIALYTRANSFERASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PROTEIN SULFOTRANSFERASES & SULFATASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ARRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CHROMATOGRAPHY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ELECTROPHORESIS INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY HPLC COLUMNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY MASS SPECTROMETRY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN LABELING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCAN PURIFICATION KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GLYCOPROTEIN LABELING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY REAGENTS & CHEMICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 60. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 61. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 62. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 63. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 64. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 65. CANADA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 68. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 109. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 110. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 111. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 112. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 113. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 114. GERMANY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 116. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 117. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 120. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 121. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 122. FRANCE GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 133. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 134. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 135. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 136. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 137. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 138. ITALY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 141. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 142. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 143. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 144. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 145. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 146. SPAIN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 172. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 173. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 174. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 175. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 176. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 177. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 178. DENMARK GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 189. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 190. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 191. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 192. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 193. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 194. QATAR GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 197. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 198. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 199. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 200. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 201. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 202. FINLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 221. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 222. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 223. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 224. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 225. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 226. EGYPT GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. TURKEY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 229. TURKEY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 230. TURKEY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 232. TURKEY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 233. TURKEY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 234. TURKEY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 245. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 246. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 247. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 248. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 250. NORWAY GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 253. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 254. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 255. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 256. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 257. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 258. POLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 276. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 278. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 279. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 280. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 281. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 282. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 283. CHINA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 286. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 287. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 288. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 289. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 290. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 291. INDIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 293. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 294. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 295. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 296. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 297. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 298. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 299. JAPAN GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 324. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 325. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 326. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 327. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 328. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 329. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 330. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 331. THAILAND GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY KITS, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 338. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 339. PHILIPPINES GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA GLYCOMICS/GLYCOBIOLOGY MARKET SIZE, BY ENZYMES

Companies Mentioned

The companies profiled in this Glycomics/Glycobiology market report include:
  • Agilent Technologies, Inc.
  • AMSBIO
  • Asparia Glycomics
  • Bio-Techne Corporation
  • Bruker Corporation
  • Chemily Glycoscience
  • Creative Diagnostics
  • FUJIFILM Wako Pure Chemical Corporation
  • Genos Glyco
  • Glycan Therapeutics
  • GlycoDiag
  • glyXera GmbH
  • ICE S.p.a.
  • Lectenz Bio, Inc.
  • Ludger Ltd
  • Megazyme Ltd. by Neogen Corporation
  • Merck KGaA
  • New England Biolabs, Inc.
  • QIAGEN N.V.
  • RayBiotech, Inc.
  • Revvity, Inc.
  • SCIEX by Danaher Corporation
  • Shimadzu Corporation
  • Sumitomo Bakelite Co., Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Tokyo Chemical Industry Co., Ltd.
  • Vector Laboratories, Inc.
  • Waters Corporation
  • Z Biotech, LLC
  • Zacharon Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Table Information